

Shionogi Selected for the Global ESG Investment Index 'FTSE4Good Index Series' and 'FTSE Blossom Japan Index', for the second consecutive year.

OSAKA, Japan, August 23, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that Shionogi has been included in the "FTSE4Good Index Series" and the "FTSE Blossom Japan Index", which are global stock indices for environmental, social and governance (ESG), for the second consecutive year.

The FTSE4Good Index Series is developed by FTSE Russell, a member of London Stock Exchange Group. It is designed based on the existing international ESG standards to select companies that demonstrate strong ESG efforts. The FTSE Blossom Japan Index is an index created by FTSE Russell which includes companies meeting clear and transparent standards with respect to environmental, social and governance practices, and it is designed to be unbiased across industries.

These indices are broadly used as important criteria by global investors who focus on each company's ESG efforts.

In our medium-term business plan STS2030, Shionogi has confirmed its material issues, and set forth its efforts to achieve the SDGs, through business activities such as protecting people worldwide from the threat of infectious diseases and contributing to the realization of a sustainable society. At the same time, we are committed to pursuing and reinforcing our responses to ESGs, supporting sustainability and driving the company's growth. Based on that commitment, Shionogi will make a concerted effort to benefits all of its stakeholder groups well into the future.



FTSE4Good



FTSE Blossom
Japan

About Shionogi's material issues:

www.shionogi.com/global/en/company/strategy/important-issues.html

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.